Argos Therapeutics Publishes Approach to Generating High-Avidity Cytotoxic T Cells with Dendritic Cell-Based Immunotherapy

Argos Therapeutics today announced the publication of a paper in the October 15th issue of the Journal of Immunonology demonstrating that the Company's proprietary RNA-electroporated dendritic cells generate high-avidity cytotoxic T cells (CTL) in vitro th... [more]

View complete Press Release article